DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20164121

Efficacy and safety of ivabradine as an add-on to atenolol in patients with chronic stable ischemic heart disease

Elavarasi Pichai, Ezhil Ramya J., Vasanth Sandanapitchai

Abstract


Background: Heart rate is the important key factor for determining the cardiac output, myocardial oxygen demand and coronary blood flow. Reduction in heart rate is the main stay of treatment for preventing and treating IHD. Due to the interactions with other drugs and adverse effects of the conventional drugs, the management of IHD focused on novel targets. Ivabradine is a novel specific and selective if current inhibitor of SA node. The objective of the study was to efficacy and safety of ivabradine as an add-on to atenolol in patients with chronic stable ischemic heart disease.

Methods: Interventional, open label, prospective clinical study was done over a period of 1 year. Single centered study conducted in 50 patients in the Outpatient Department of cardiology, Tirunelveli Medical College Hospital, Tirunelveli. Endpoints noted were reduction in resting heart rate using 12 lead ECG and improvement in Canadian cardiovascular society (CCS) class of angina grading.

Results: Ivabradine in reducing the heart rate at the end of 1 month (86.60±9.16) and at the end of 3 months (81.82±8.37) compared with baseline (93.08±11.67). CCS class of grade of angina also improved at the end of one month and 3 months compared with baseline. Grade IV (3 - 0 - 0), grade III (7 - 3 - 1) and grade II (40 - 8 - 9).

Conclusions: Ivabradine is safe and effective in preventing and treating further anginal attacks in patients with chronic stable ischemic heart disease already on atenolol therapy.


Keywords


Canadian cardiovascular society class of angina, Ivabradine, If current, Ischemic heart disease

Full Text:

PDF

References


Jackson JM. Ivabradine - a novel treatment for chronic stable angina. Drugs in Context: e212225. DOI: 10.7573/dic.212225.

Cassar A, Holmes DR, Rihal CS. Chronic coronary artery disease: diagnosis and management. Mayo Clin Proc. 2009;84(12):1130-46.

Morrow DA, Boden WE. Stable Ischemic Heart Disease. Braunwald’s Heart Disease, A textbook of cardiovascular Medicine. Philadelphia Elsevier. 2012. pp. 1210-1211.

Deedwania P. Selective and specific inhibition of if with ivabradine for the treatment of coronary artery disease or heart failure, drugs. Springer. 2013;73:1569-86.

ZakyH, Elzein H, Alsheikh-Ali AA, Al-Mulla A. Short-term effects of ivabradine in patients with chronic stable ischemic heart disease. Heart Views 2013;14:53-55.

Pflieger M. Management of stable coronary artery disease. American Family Physician. 2011;83(7):820-5 .

Hjemdahl P, Eriksson SV, Held C, Forslund L, Näsman P, Rehnqvist N. Favourable long term prognosis instable angina pectoris: An extended follow up of the angina prognosis study in Stockholm (APSIS). Heart. 2006;92:177‑82.

Ferrari R, Campo G, Gardini E, Pasanisi G, Ceconi C. Specific and selective If inhibition: expected clinical benefits from pure heart rate reduction in coronary patients. European Heart Journal Supplements. 2005;7(Supplement H):H16-21.

Shattock M, Camm AJ. Pure Heart Rate Reduction: The If Channels From Discovery to Therapeutic Target. Br J Cardiol. 2006;13(1):27-35.

Michel T. Treatment of Myocardial Ischemia and Hypertension. Goodman and Gilman’s The Pharmacological Basis Of Therapeutics, New York: McGraw-Hill. 2011;27:772-3.

Kones R. Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction and revascularization. Vascular Health and Risk Management. 2010;6:749-74.

Michel T, Hoffman BB. Treatment of Myocardial Ischemia and Hypertension .Goodman and Gilman’s The Pharmacological basis of therapeutics, New York: McGraw-Hill. 2011;27:757-773.

Di Franco A, Sarullo FM, Salerno Y. Beta-blockers and ivabradine in chronic heart failure: from clinical trials to clinical practice. Am J Cardiovasc Drugs. 2014;14(2):101-10.

Sulfi S, Timmis AD. Ivabradine - the first selective sinus node If channel inhibitor in the treatment of stable angina. Int J Clin Pract. 2006;60(2):222-8.

Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation. 1999;99(9):1165-72.

Peters SAE, Woodward M, Lam TH, Suh II. Sex disparities in risk and risk factors for ischemic heart disease in the Asia-Pacific region. Europ Jou Preven Cardiolo. 2014;21(5):639-46.

Jochmann N. Effect of ivabradine-induced heart rate reduction on flow-mediated dilation measured with high-sensitivity ultrasound in patients with stable coronary heart disease. Cardiovascular ultrasound. 2014;12(5):1-6.

Lopez E, Lopez J. beta blockers. Pharmacological Treatment of Chronic Stable Angina Pectoris. Current cardiovascular therapy. Springer international New York. 2015. pp.57-70.

Chaturvedi A, Singh Y. Comparison of the efficacy and tolerability of ivabradine and ranolazine in patients of chronic stable angina pectoris. Journal of pharmacology and pharmacotherapeutics. 2013;4(1):33-8.

Borer JS, Jaillon P. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107(6):817-23.

Marquis-Gravel G, Tardif JC. Ivabradine: the evidence of its therapeutic impact in angina. Core Evid. 2008;3(1):1-12.

Hochman JS, Ruzyllo W. Coronary Intervention for Persistent Occlusion after Myocardial Infarction. N Engl J Med. 2006;355(23):2395-407.